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Abstract
The human epithelial cell adhesion molecule (EpCAM) is highly expressed in a variety of clinical tumour entities. Although
an antibody against EpCAM has successfully been used as an adjuvant therapy in colon cancer, this therapy has never
gained wide-spread use. We have therefore investigated the possibilities and limitations for EpCAM as possible molecular
imaging target using a panel of preclinical cancer models. Twelve human cancer cell lines representing six tumour entities
were tested for their EpCAM expression by qPCR, flow cytometry analysis and immunocytochemistry. In addition, EpCAM
expression was analyzed in vivo in xenograft models for tumours derived from these cells. Except for melanoma, all cell lines
expressed EpCAM mRNA and protein when grown in vitro. Although they exhibited different mRNA levels, all cell lines
showed similar EpCAM protein levels upon detection with monoclonal antibodies. When grown in vivo, the EpCAM
expression was unaffected compared to in vitro except for the pancreatic carcinoma cell line 5072 which lost its EpCAM
expression in vivo. Intravenously applied radio-labelled anti EpCAM MOC31 antibody was enriched in HT29 primary tumour
xenografts indicating that EpCAM binding sites are accessible in vivo. However, bound antibody could only be
immunohistochemically detected in the vicinity of perfused blood vessels. Investigation of the fine structure of the HT29
tumour blood vessels showed that they were immature and prone for higher fluid flux into the interstitial space. Consistent
with this hypothesis, a higher interstitial fluid pressure of about 12 mbar was measured in the HT29 primary tumour via
‘‘wick-in-needle’’ technique which could explain the limited diffusion of the antibody into the tumour observed by
immunohistochemistry.
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Introduction
Detectionofcancercellsandmorespecificallythecharacterisation
of metastatic cancer cells in a non-invasive way is a primary aim of
molecularimaging.SeveralapproachessuchasMagneticResonance
Imaging(MRI),PositronEmissionTomography(PET),andOptical
Imaging techniques were invented for this purpose. All applications
require specific probes against antigens that are highly expressed on
the surface of human cancer cells. For promising probes, a specific
tumour uptake in vivo has been demonstrated after systemic
administration via intravenous application in appropriate animal
models [1]. The overall probe biodistribution and more specifically
the histological distribution of the bound probe within the tested
tumour should be analysed inthese models.
The epithelial cell adhesion molecule (EpCAM; CD326) is
membranous 38-kDa glycoprotein which is highly expressed in
cancer tissue of different entities and to a lower extent by normal
epithelium [2,3]. Elevated EpCAM expression was confirmed
amongst other tumour entities in breast, pancreatic, colon,
prostate and lung cancer [4,5,6,7]. The impact of high EpCAM
expression on patient’s survival is still an ongoing debate. High
EpCAM expression was associated with poor survival rates for
breast, gall bladder and squamous cell carcinoma of the esophagus
whereas better survival rates were reported for renal cell
carcinoma and pancreatic cancer [8,9,10,11,12]. The correlation
of EpCAM expression and clinical outcome therefore depends on
the cancer entity.
EpCAM was the first target for monoclonal antibody therapy
against human cancer. Furthermore, the first successful antibody
based therapy judged by of overall survival was achieved using an
anti EpCAM antibody [13,14]. Several studies for non-invasive
monitoring of cancer cells in xenograft mouse models with
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metastatic behaviour of human pancreatic cancer cells to lymph
nodes were investigated using a near-infrared fluorophore labelled
EpCAM [15]. A study with a mouse xenograft model showed that
fluorescent intravital live microscopy with a probe against EpCAM
antigen could successfully be used for monitoring tumour resection
in vivo [16]. HNSSC (Squamous cell carcinoma of the head and
neck) xenotransplanted severe combined immunodeficient (SCID)
mice were treated with radioimmunotherapy against EpCAM
positive cells and biodistribution of EpCAM-directed monoclonal
antibodies were investigated in EpCAM-transgenic mouse models
[17,18].
To investigate the capabilities and limitations of molecular
imaging based on specific antibodies we developed murine
xenograft models for in vivo detection of EpCAM using the
monoclonal antibody MOC31.
This contribution describes the expression of EpCAM in 12
human cancer cell lines in vitro and in vivo in related primary
tumours that were developed in xenograft models. With one of
these models we also investigated the accessibility of EpCAM to
antibodies in the primary tumour after i.v. application of the anti
EpCAM antibody MOC31. We have analyzed the distribution of
the MOC31 antibody as well as the interstitial fluid pressure (IFP)
in these tumours since enhanced IFP represents an obstacle for
efficient delivery of i.v. applicated drugs [19,20]. Our results
indicate that EpCAM expression is wide-spread over all tumours
used making it an ideal target for imaging/therapeutic purposes.
However, if MOC31 is applied i. v., binding of MOC31 was
limited to tumour cells around blood vessels. The increased IFP in
tumours could explain the limited distribution over the entire
tumour volume. Lowering IFP could therefore be essential to
increase the tumour penetration of i. v. applied antibodies directed
against tumour antigens.
Materials and Methods
Cell Lines
The human prostate cancer cell lines LNCAP and PC3 (both
established from metastatic adenocarcinomas) were obtained from
the German Collection of Microorganisms and Cell Culture
(DSMZ, Germany). The human breast cancer cell lines T47D and
MCF7 (both established from pleural effusions) were obtained
from European Cell Culture Collection (Porton Down, Wiltshire,
UK). The human melanoma cell lines MEWO [21] and FemX-1
[22] (both established from metastatic melanoma lymph nodes)
were kindly provided by the Klinik fu ¨r Dermatologie, Universi-
ta ¨tsklinikum Hamburg-Eppendorf, Germany. The human colon
cancer cell line HT29 (established from a primary carcinoma of
the colon) was obtained from Cell Lines Service (Germany). The
human colon cancer cell lines Caco2 and SW480 (both established
from a primary adenocarcinoma of the colon) were obtained from
European Cell Culture Collection (Porton Down, Wiltshire, UK).
The human small cell lung cancer cell line OH-1 (established from
pleural effusion) was kindly provided by Prof. Uwe Zangemeister-
Wittke, University of Bern, Department of Pharmacology [23].
Two human pancreatic cancer cell line 5061, established from an
advanced pancreatic adenocarcinoma and 5072 m, established
from an advanced pancreatic adenocarcinoma from a 71-year-old
Caucasian woman, were kindly provided by the Klinik und
Poliklinik fu ¨r Allgemein-, Viszeral- und Thoraxchirurgie, Uni-
versita ¨tsklinikum Hamburg-Eppendorf, Germany [24]. Written
informed consent of the patient for the removal of tissue samples
for investigational purposes was obtained prior to surgery. The
study was approved by the ethical committee of the Medical
Council of Hamburg (A ¨rztekammer), Germany.
The LNCAP, PC3, T47D, MCF7, MEWO, FemX-1, HT29,
Caco2, SW480, OH-1 cells were cultured in vitro under standard
cell culture conditions (37 ˚C, 100% relative humidity, 5% CO2) in
RPMI medium (Gibco/Life Technologies, Paisley, Scotland)
supplemented with 10% heat inactivated fetal bovine serum
(FBS, Gibco), 2 mM L-glutamine (Gibco), 100 U/ml penicillin
and 100 mg/ml streptomycin (Gibco). The cells 5061 and 5072
were cultured in complete (TUM) RPMI 1640 medium with
Glutamax (Invitrogen, NY, USA) supplemented with 10% of fetal
calf serum (FCS), 200 IU/ml of penicillin-streptomycin, 0.1 mg/
ml gentamycin (Biochrom AG, Berlin, Germany), 50 mM of
human transferrin (Sigma-Aldrich, Steinheim, Germany),
0.01 mg/ml of bovine insulin (Sigma-Aldrich, Steinheim, Ger-
many), 0.01 mg/ml of recombinant human epidermal growth
factor (Pepro Tech, London, UK), and 0.01 mg/ml of human
basic fibroblast growth factor (Pepro Tech, London, UK). Before
reaching confluence, cells were routinely harvested for passaging
using 0.05% trypsin-0.02% EDTA (Gibco).
Real-time PCR
To quantify EpCAM mRNA amount in relation to glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) mRNA amount of
the human tumour cells, real-time PCR was performed. In brief,
total RNA from tumour cells was isolated using RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. The RNA was eluted in 50 ml RNase free water.
The RNA-concentration was measured and the quality was
checked on a NanoDropH ND-1000 Spectrophotometer (Peqlab,
Erlangen, Germany). The cDNA synthesis was performed in
a Biometra thermal cycler (Biometra, Go ¨ttingen, Germany) in
a total volume of 20 ml for each sample and followed the
manufacturer’s instruction for the First Strand Transcriptor cDNA
Synthesis Kit (Roche Diagnostics, Mannheim, Germany). Two
parallel cDNA approaches were used for reverse transcription
separately, with anchored-oligo(dT)18 and random hexamer
primer. Two mg of total RNA were used for each cDNA approach
and were pooled afterwards. The oligo-dT primers transcribe the
mRNA with poly-A sequences and the random primed cDNAs
transcribe fragmented RNA. The pooled primers cover therefore
all putative EpCAM transcripts. Real-time polymerase chain
reaction was performed in a 96 well format with the LightCyclerH
480 System (Roche Diagnostics GmbH, Mannheim, Germany).
For the real-time PCR, the LightCycler Fast Start DNA
MasterPLUS SYBRGreen I Kit (Roche Diagnostics GmbH,
Mannheim, Germany) was used. Two ml of cDNA were used as
a template for the PCR reaction and incubated in a total reaction
volume of 10 ml, containing 16SYBR Green I Master mix
including Taq DNA polymerase, Taq PCR buffer, a dNTP
mixture and 1 mM MgCl2, 10 pmol specific EpCAM or GAPDH
primers. Forward EpCAM primer (CTG GTG TGT GAA CAC
TGC TGG GG), reverse EpCAM primer (TCT CCT TCT GAA
GTG CAG TCC GC), forward GAPDH primer (AAA TTG
AGC CCG CAG CCT CCC), and reverse GAPDH primer (CCA
GGC GCC CAA TAC GAC CAA AT) were synthesized by
MWG-BIOTECH AG (Ebersberg, Germany). The PCR condi-
tions were initially 5 min 95uC, followed by 40 cycles of 10 s 95uC,
10 s 67uC (EpCAM) or 72uC (GAPDH) and 20 s 72uC,
respectively.
Protein Extraction and Western Blotting
Total protein extracts from cell lines were obtained by lysing the
cells in cold radioimmunoprecipitation assay (RIPA) buffer
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NaCl) in the presence of protein inhibitor cocktail set I
(Calbiochem, La Jolla, USA). After centrifugation to remove cell
debris, protein concentrations of the supernatants were measured
using the BCA method. 40 mg protein per lane were resuspended
in loading buffer (0.5 M Tris-HCl, pH 6.8, glycerol, 10% SDS,
0.5% bromphenol blue, mercaptoethanol) and then subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (8%
gels). Subsequently, proteins were blotted onto a nitrocellulose
membrane (HybondH-ECLH, Amersham Biosciences, Freiburg,
Germany) following conventional protocols. Finally, blots were
blocked in 4% bovine serum albumin/Tris-buffered saline–0.1%
Tween 20 (TBS-T) for 30 min at room temperature. Membranes
were incubated with primary antibody MOC31 (1 mg/ml,
DakoCytomation, Carpinteria, USA) and anti-beta-Actin
(0.5 mg/ml, Abcam, Cambridge, UK) over night at 4uC, washed
with TBS-T and incubated with a 1:200 diluted polyclonal goat-
anti-mouse antibody (DakoCytomation, Carpinteria, USA) con-
jugated with horseradish peroxidase for 60 min at room
temperature. The bound immune complexes were visualised using
ECL Western Blotting Substrate (Pierce, Rockford, USA) and the
ChemiDoc XRS System (Bio-Rad, Munich, Germany).
Flow Cytometry
Cultured cells were detached with Cell Dissociation Buffer
(GIBCO
TM, Carlsbad, US) and incubated on ice for 30 min with
MOC31 (DakoCytomation, Carpinteria, USA) primary antibody
at a concentration of 1 mg/ml. The corresponding murine isotype
control was IgG1 (DakoCytomation, Carpinteria, USA). The cells
were washed and the primary antibody was detected with
allophycocyanin-conjugated goat-anti-mouse antibody (Becton
Dickinson Biosciences, Heidelberg, Germany). Flow cytometry
was performed using a FACS CALIBUR flow cytometer (Becton
Dickinson, Heidelberg, Germany). Data were analysed using Win
MDI 2.9 software.
Immunocytochemistry
For immunocytochemistry, cells cultured in eight-well chamber
slides (Becton Dickinson, Heidelberg, Germany) were washed
with PBS, fixed in ice-cold acetone for 2 min, air dried, and
blocked with 10% rabbit sera in blocking reagent (TBS). Slides
were incubated with MOC31 or IgG1 control antibody,
respectively at a dilution of 0.6 mg/ml over night (4uC) then
followed by a biotinylated rabbit anti mouse antibody (DakoCy-
tomation) at a dilution of 1:200 for 30 min. After careful washes
in TBS, an incubation with an avidin-alkaline phosphatase
complex (ABC kit, Vectastain, Vector, Burlingame, CA) for
30 min followed and thereafter, additional washes in TBS were
performed. Alkaline phosphatase activity was visualised using
Naphthol-AS-bisphosphate as a substrate and New Fuchsin was
used for simultaneous coupling. Slides were counterstained with
Mayer’s hemalum diluted 1:1 in distilled water for ten seconds,
blued under running tap water and mounted with AquatexH
(Merck KGaA, Darmstadt, Germany).
Immunohistochemistry of Tumour Cell Lines
Xenotransplanted in SCID Mice
Sections of all primary tumours were drawn from our in house
tumour bank. They all had been fixed with 4% formalin and
embedded in paraffin wax according to standard procedures. For
immunohistochemistry, 5 mm thick sections were cut, dewaxed
and treated with bacterial Type XXIV Proteinase (Sigma-Aldrich,
Steinheim, Germany) at a dilution of 40 mg/100 ml for 10 min at
37uC. After washing, non-specific binding was blocked by
incubating sections in 10% normal rabbit serum (DAKO,
Hamburg, Germany) for 30 min at room temperature. The
following steps were performed as described above. The intensity
(plus signs) and extent (percentage) of the positive areas of five
histological sections were determined by visual inspection of three
independent observers. The plus sign indicates the intensity of the
staining. It ranges from ‘‘2’’ to ‘‘+++’’. The percentage indicates
how many cells were labelled.
Subcutaneous Implantation of HT29 Cells
To investigate EpCAM binding sites in vivo, specific pathogen-
free BALB/c SCID (scid/scid) mice were used. The mice were 8–
16 weeks old and weighed 20–30 g at the beginning of our
experiments. They were housed in filter top cages and provided
with sterile water and food ad libitum. For injection, HT29
carcinoma cells were harvested by trypsination and viable cells
(5610
6) were suspended in 1 ml of cell culture medium. An aliquot
of 200 ml of this suspension was injected subcutaneously between
the scapulae of each SCID mouse. Six mice bearing carcinomas
were included in the experiment when the tumour had reached
maximal growth or started to ulcerate.
Iodination of Antibodies
Iodination of antibodies was done by Iodobeads (Pierce,
Rockford, USA). Specifically, 10 ml sodium [125I]Iodine
(3.7 MBq/ml, Amersham, UK) was added to 1 mg MOC31 or
control IgG1 in 1 ml PBS in the presence of one Iodobead and the
reaction was left for 15 min. Free [125I]Iodine was removed by
exclusion chromatography through a PD-10 column (GE
Healthcare, Buckinghamshire, UK). The protein concentration
was determined with the BCA method and the specific activity of
the [125I]-EpCAM and [125I]-IgG1 per mg protein was measured
by gamma counting (Perkin Elmer, Waltham, USA).
Application of Radioactive Antibodies
Ten mg of [125I]-labelled antibodies were injected via tail vein
into HT29 carcinoma bearing mice. Three mice received control
[125I]-IgG1 and three mice the specific anti EpCAM [125I]-
MOC31 antibody. After 24 hours blood samples were taken by
heart puncture. Afterwards mice were sacrificed, intracardially
perfused with NaCl and tumour and organs were removed and
weighted. Radioactivity of organs, tumours and blood was
determined with the gamma counter. Statistical analyses (Two-
way ANOVA) were performed using GraphPad Prism 5 software
(GraphPad software, USA).
Application of Evans Blue
Evans Blue was injected i.v. at a dose of 25 ml (50 mg/ml PBS)
per HT29 s. c. bearing mouse 4 hours before sacrifice.
Anaesthetised mice were intracardially perfused with 1% BSA in
NaCl to remove free dye and afterwards fixed with 4% PFA.
Tumours were removed and embedded in 5% agarose gel, cut in
200 mm thick slices with a vibratome (VT1000E, Zeiss, Wetzlar,
Germany) and scanned with 2400 dpi on a scanner (Epson, Long
Beach, USA).
Examination of Tumour Blood Vessels
Blood vessels of HT29 tumours were visualized as previously
described [25]. Briefly, anaesthetised mice were intracardially
perfused consecutively with 2 ml PBS to remove blood, 10 ml of
DiI solution with a concentration of 1.2 mg DiI in a mix of PBS
and 5% glucose at a ratio of 1:4, and finally with 5 ml 4% PFA.
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described above. Laser-scanning confocal microscopy was con-
ducted using a Nikon A1R confocal microscope with a 561 nm
diode pumped solid state laser (DPSSL) and with plan apo 610/
0.45 numerical aperture (NA) or plan fluo oil 640/1.3 NA
objective lenses. Image analysis and in particular 3D reconstruc-
tion of blood vessels was achieved using NIS-Elements AR
software (Nikon Corporation, Japan).
Measurement of Interstitial Fluid Pressure (IFP)
IFP was measured with a modified wick-in-needle (WIN)
technique [26,27]. In brief, a 21 gauge needle was prepared with
a2 61 mm long side-hole 2 mm distant from the tip. The needle
was filled with 4 (6-0 Ethilon) nylon surgical sutures (Ethicon,
Norderstedt, Germany) and the tip was closed with acrylic glue
(Uhu, Bu ¨hl, Germany). The needle was connected to a MSD 100
pressure transducer (SiKA, Kaufungen, Germany) connected by
polyethylene tubing filled with sterile, heparinised (10 units/ml)
saline. The pressure transducer was connected to handheld
double-pressure-meter (model MH3156; SiKA, Kaufungen,
Germany) and the signal was recorded with a computer with
integrated software (GSOFT3050; SiKA, Kaufungen, Germany).
The needle was inserted into the middle of the tumour after the
pressure level was set to zero. After reaching a constant pressure
level (measured value) the fluid communication between pressure
sensor and needle was tested as the tubing was compressed with
a screw clamp (arrow b) which results in a sharp increase of the
pressure, then an exponential decrease, followed by another
period of stabilization before decompressing the tubing (arrow c)
which produces a rapid decrease and an exponential increase.
Magnetic Resonance Imaging
Magnetic resonance imaging examinations were performed
using a 7-Tesla Bruker Clinscan animal MRI scanner and a four-
channel phased-array surface coil (Bruker BioSpin MRI GmbH,
Ettlingen, Germany). All of the mice were anaesthetised
continuously with inhaled isofluorane (1.5–2%). During MR
examination an integrated thermocouple/heater system to regu-
late body temperature of mice was used for signal reception. MR
imaging was performed using a two-dimensional turbo spin-echo
(TSE) sequence (TR/TE/flip=1480 ms/36 ms/180u, NEX=16,
FOV=30 mm626.3 mm) and 24 contiguous 400-mm-thick axial
slices were acquired (pixel size=11761176400 mm
3). Total scan
time per animal was approximately 8 min. Image analysis was
performed using Image Processing and Analysis in Java (ImageJ,
version 1.44 p).
Ethics Statement
The methodology for carrying out the experiment was
consistent with the UKCCCR guidelines for the welfare of
animals in cancer research. The experiment was supervised by the
institutional animal welfare officer and approved by the local
licensing authority (Beho ¨rde fu ¨r Soziales, Familie, Gesundheit und
Verbraucherschutz; Amt fu ¨r Gesundheit und Verbraucherschutz,
Hamburg, Germany, project no. 92/09).
Results
EpCAM Expression of Tumour Cell Lines in vitro and
in vivo
The EpCAM mRNA and protein expression levels of twelve
human cancer cell lines representing six different tumour entities
were investigated by qPCR, FACS analysis and immunocyto-
chemistry. Furthermore, EpCAM abundance was analyzed by
immunostaining of paraffin sections from tumours that were
derived from the same cell lines.
The three different colon cancer cell lines displayed high
(HT29) to medium (Caco2) to low (SW480) EpCAM mRNA levels
in vitro as determined by qPCR (see Figure 1A). Analysis of
EpCAM protein abundance was performed using the monoclonal
MOC31 antibody. The antibody was highly specific and
recognized a band of expected size in Western Blot analysis of
cell lysate from HT29 cells (see Figure 1B). In addition, we
detected a previously described second band presumably repre-
senting a glycosylated form of EpCAM [28]. Analysis of EpCAM
protein expression at the cell surface by flow cytometry revealed
high EpCAM expression level in HT29, Caco2 and to a lesser
extent in SW480 cells (see Figure 1C). Comparable immunore-
activity for EpCAM was observed by immunostaining of HT29,
Caco2 and SW480 cells in vitro and in corresponding tumours
in vivo (see Figure 2).
The 5061 and 5072 pancreatic cancer cell lines showed medium
to low EpCAM mRNA levels in vitro (see Figure 1A). Flow
cytometry analysis revealed high EpCAM protein expression on
the cell surface in both cell lines (see Figure 1C). Similarly, high
EpCAM immunoreactivity was also observed in both cell lines
when grown in vitro (see Figure 2). However, the immunoreactivity
of the cells in vivo grown as xenografts showed different results:
5061 primary tumours were highly positive for MOC31 binding
whereas in 5072 tumours the MOC31 immunoreactivity could not
be detected (see Figure 2).
Prostate cancer cell lines displayed in vitro medium (PC3) and
high (LNCAP) levels of mRNA for EpCAM (see Figure 1A). Cells
of both cell lines showed high abundance of membrane bound
EpCAM protein and strong MOC31 immunoreactivity of in vitro
grown cells (see Figures 1C and 2, respectively). Tumours of both
cell lines were strongly positive for MOC31 immunoreactivity (see
Figure 2).
T47D and MCF7 cell lines derived from breast cancer showed
medium levels of EpCAM mRNA expression (see Figure 1A). Both
cell lines were strongly positive for EpCAM immunoreactivity in
flow cytometry analysis (see Figure 1C) and also after staining of
cells in vitro (see Figure 2). In contrast, primary T47D and MCF7
tumours grown in vivo showed a decreased immunoreactivity for
MOC31 binding (see Figure 2).
OH-1 cells representing small cell lung cancer showed in vitro
low EpCAM mRNA levels (see Figure 1A), although they were
highly positive for membrane bound EpCAM protein in flow
cytometry analysis (see Figure 1C). These results were confirmed
in immunocytochemistry of cells grown under cell culture
conditions (see Figure 2). In contrast, OH-1 cells grown in vivo in
immunodeficient mice displayed a low MOC31 immunoreactivity
(see Figure 2).
Our analysis of MEWO and FemX-1 cell lines that are both
derived from melanoma revealed that no EpCAM mRNA
expression could be detected. Also EpCAM protein immunoreac-
tivity was below detection limits in the melanoma cell lines in vitro
and in vivo (see Figures 1A, 1C, 2).
EpCAM Binding Detection in vivo
To analyse whether the EpCAM binding sites detected in
tissue sections were also accessible in vivo, [125I]-labelled MOC31
mAb and non-specific [125I]-labelled control IgG were injected
into the tail vein of SCID mice bearing HT29 colon carcinoma
(see Figure 3). A three-fold higher enrichment of the [125I]-
MOC31 mAb in the HT29 primary colon carcinoma was
detected compared to the [125I]-IgG1 control (see Figure 4).
This enrichment was statistically highly significant (two-way
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36258Figure 1. EpCAM expression of human malignant cells. (A) The mRNA of the malignant cell lines 5061, 5072 (pancreatic cancer), LNCAP, PC3
(prostate cancer), FemX-1, MEWO (melanoma), T47D, MCF7 (breast cancer), HT29 (colon cancer) and OH-1 (small cell lung cancer) were relatively
quantified by qPCR, using GAPDH for normalization. 5072, LNCAP, PC3, T47D, MCF7, Caco2 and HT29 showed high expression levels of EpCAM
mRNA. (B) EpCAM could be detected by Western blot analysis of HT29 cell lysate with a specific binding to antibody MOC31. Beta-actin was used as
loading control. (C) EpCAM could positively be detected by flow cytometry analysis with MOC31 on all cancer cell lines, except of FemX-1 and MEWO.
Isotype controls are shown as dotted lines.
doi:10.1371/journal.pone.0036258.g001
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enrichment of the specific [125I]-MOC31 mAb compared with
control [125I]-IgG could be observed (two-way ANOVA,
P,0.01, see Figure 4).
In a parallel experiment the distribution of the injected mAbs
24 hours after application was analysed in histological sections
(see Figure 5). No detectable levels of antibody could be found in
control animals injected with control IgG1 mAb. In contrast,
MOC31 binding could be detected in the vital zones of the
HT29 tumour around blood vessels both in the margin of the
tumour and in blood vessels located in more central areas of the
tumour. However, most parts of the tumour tissue remained
unstained.
To study the mechanism of the limited MOC31 penetration
into the HT29 tumour tissue we investigated the permeability of
the tumour blood vessels with an alternative technique. We
injected the albumin-binding dye Evans Blue i.v. into mice bearing
HT29 colon carcinoma and investigated the dye distribution in
vibratome sections of the tumour. Evans Blue-Albumin complexes
were present primarily at the margin and around blood vessels in
Figure 2. EpCAM protein expression pattern in vivo and in vitro. 5061, LNCAP, PC3, T47D, HT29, and Caco2 cells showed in vitro and in vivo
strong binding of MOC31 by all cells. In contrast, MCF7, OH-1, SW480 and particularly 5072 cells showed strong MOC31 in vitro binding, but little or
no binding in vivo. MEWO and FemX-1 cells showed no MOC31 binding in vitro and in vivo. (red=MOC31 binding).
doi:10.1371/journal.pone.0036258.g002
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Blue-Albumin distribution was similar to the pattern of MOC31
distribution after systemic application of both molecules.
To visualize the distribution and fine structure of HT29
xenograft blood vessels we used an already described DiI perfusion
protocol [25]. Well perfused blood vessels were mainly located at
the margins and to a lesser extent in the centre of the tumour (see
Figure 7A). Higher magnifications and 3D reconstruction of the
blood vessels showed that they are highly irregular and could be
described as immature (see Figures 7B, C).
In order to measure the interstitial fluid pressure (IFP) within
primary tumours we have established the ‘‘wick-in-needle’’
technique according to the protocol of Boucher et al. In our
hands, the interstitial pressure reacted to controlled compression
and decompression of the tubing connected to the needle in the
expected fashion (see Figure 8A) [27]. We have determined the
IFP of six different HT29 tumour xenografts and observed
interstitial pressure levels ranging from 6 to 17 mbar with a mean
IFP of 11.9+/24 mbar (see Figure 8B).
Discussion
This study investigates the possibilities of using anti EpCAM
antibodies as a tool for molecular imaging purposes. We used
monoclonal antibody MOC31, which was already described by de
Jonge in 1993 as a suitable antibody for molecular imaging [29].
Despite of early reports, no clinical development followed with this
antibody similar to many other antibodies developed during this
time. Therefore, we examined EpCAM expression in a panel of
human cancer cell lines and their respective primary tumour
xenografts in immunodeficient SCID mice in order to identify
a suitable model for the analysis of the accessibility of MOC31 to
EpCAM located on the cell surface of cells in primary tumour
xenografts. The results of our expression analysis are summarized
in Table 1.
The mRNA expression levels for EpCAM of twelve human
cancer cell lines were analyzed in vitro by qPCR. The protein
abundance on the cell surface was analyzed by flow cytometry and
immunocytochemistry under cell culture conditions (see Figure 1
and Table 1). Remarkably, almost all cell lines (except of
melanoma cell lines) of the different entities had similar levels of
EpCAM protein, although they exhibited different mRNA
expression levels. A discrepancy between mRNA levels and
protein abundance has already been described for other proteins
like Period2 and CEACAM [24,30]. Differences in mRNA
stability are and/or protein turnover are most likely responsible
for this phenomenon. However, differences regarding EpCAM
mRNA stability among the tumour cell lines used in this study
have not yet been investigated. Since the mRNA concentration
was not directly related to the measured protein, we were
interested in how the protein expression is altered under in vivo
conditions. For most of the cell lines analyzed we found that levels
of EpCAM abundance were similar between cells grown in culture
(in vitro) and cells grown as a primary tumour in a xenograft model
(in vivo) judged by immunoreactivity of the MOC31 antibody (see
Figure 3. MRI of HT29 xenograft. HT29 colon carcinoma (a) grown
at the subcutaneous injection site above muscles (b) appear hyper-
intense in two-dimensional turbo spin-echo (TSE) sequence (MR images
in axial orientation).
doi:10.1371/journal.pone.0036258.g003
Figure 4. EpCAM in vivo binding. [125I]-Labelled specific anti EpCAM MOC31 and non-specific [125I]-labelled IgG1 antibody were used for EpCAM
in vivo binding in HT29 carcinoma bearing SCID mice. There is a significant difference between specific and control antibody by HT29 carcinoma, but
except for spleen and blood not in other organs (two-way ANOVA, P,0.001, n=3). Standard deviations are indicated by bars.
doi:10.1371/journal.pone.0036258.g004
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5072 in which almost no EpCAM protein expression could be
detected in vivo. A similar difference in expression levels has already
been described for this cell line regarding the abundance of the
CEACAM protein family members [24]. However, the fact that
the majority of cancers expressed EpCAM in vivo and our results
indicate that EpCAM expression in tumours is not a limiting factor
for its usage for specific targeting.
Next we investigated the binding of the MOC31 antibody to
EpCAM expressed on the surface of tumour cells in vivo. Injection
of radio-labelled MOC31 antibody or non-specific IgG1 antibody,
respectively, into HT29 primary colon cancer xenografted SCID
mice revealed, that considerable more radioactivity was present if
the MOC31 antibody was applied instead of the control IgG1
antibody (see Figure 4). In addition to the enrichment of MOC31
in the tumour itself a significant MOC31 accumulation was
observed in the spleen (see Figure 4). This off-target phenomenon
was already observed in a study of carcinoma xenografts in nude
rats with injected [111In]-labelled MOC31 [29] and occurs in
mice as well. The enrichment of the detached [111In]-label in
phagocytic cells or Fc-receptor mediated binding of the injected
antibody was proposed to be responsible for this effect which has
to be taken into account in future studies.
To analyse the MOC31 distribution pattern after i.v.
application, we tested the tumour penetration of the MOC31
antibody by immunohistochemistry. Only few regions of the
tumour tissues around the blood vessels were positive for injected
MOC31 antibody if detected by immunohistochemistry (see
Figure 5), whereas the bulk of the tumour tissue was not
penetrated by the injected antibody explaining why the tumour
enrichment of MOC31 was only about threefold. The same
distribution pattern around the blood vessels was observed in
another model system using anti CEACAM antibodies in
a melanoma xenograft model [24] indicating that this observa-
tion of limited antibody distribution is not particular to the
HT29 xenograft model. Tumour penetration was additionally
investigated with a second neutral marker using an alternative
approach. Albumin-bound Evans Blue was visualized on tumour
vibratome slices and again could only be detected in the near
vicinity of blood vessels (see Figure 6). The pattern of staining
related to diffusion and the pattern of distribution of bound
MOC31 antibodies to cells within the tumours was similar
indicating, that limited diffusion of the antibodies could be the
reason for the restricted pattern of targeted EpCAM labelling in
MOC31 perfusion experiments. Based on the fact that only
a small part of the tumour mass was accessible to the MOC31
antibodies we argue that the actual enrichment of MOC31 in
perfused areas of the primary tumours is much higher than
estimated since the entire tumour mass was used for the
calculation of specific enrichment in our experiments.
To examine why the specific antibody could not reach all the
possible binding sites within the tumour we visualized the existing
blood vessels of HT29 tumour xenografts. Dense vascularisation
Figure 5. EpCAM in vivo detection of HT29 tumour. MOC31-antibody binds to HT29 tumour cells in vivo after i.v. injection of 10 mg MOC31mAb
in tumour bearing mice, as visualized with subsequent immunostaining against MOC31-antibody (red=MOC31 positive cells) in cryostat sections of
the primary tumour. Controls using 10 mg IgG1 mAb confirmed the high specificity of MOC31 binding to tumour cells in vivo. The specific antibody
MOC31 binding to the tumour cells was restricted to areas of the tumour, which were well supplied with blood vessels. Corresponding liver sections
showed the intake of both antibodies by cells of the RES system.
doi:10.1371/journal.pone.0036258.g005
Figure 6. Evans Blue-Albumin complex distribution in vibra-
tome sections of HT29 carcinoma. Evans Blue-Albumin complex
positive areas (blue) are recognizable at blood vessels in vital tumour
tissue (b), to a higher degree at well perfused areas at the margin of the
tumour (a) and in the transition between vital tumour tissue and
necrosis (c).
doi:10.1371/journal.pone.0036258.g006
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blood vessels were irregular and were denoted as immature (see
Figure 7). Immature blood vessels together with sparsely existing
lymph vessels were proposed to lead to elevated interstitial fluid
pressure (IFP) of the tumours [31]. We therefore measured the
IFP in HT29 tumours. Indeed, we could ascertain an increased
IFP ranging from 6 to 17 mbar compared to the IFP of normal
tissue (see Figure 8). The reliability of IFP measurements could
generally be affected by the positioning of the needle within the
tumour. In fact, our data show different IFP for six individual
tumours analyzed. However, IFP in all tumours was increased
compared to control levels that are already described [32]. Thus,
in addition to the fact that the vascularisation of the tumours
analyzed was inhomogeneous, the increased IFP could contribute
to the limited diffusion of antibodies beyond the perivascular
area and into the poorly vascularised regions of the tumours
[19].
The penetration of antibodies into the tumours could generally
also be affected by the tumour microenvironment including the
relative perfusion rates as well as the microvessel density and
leakiness that were not investigated in this study. However, the
hypothesis that limited penetration of molecules into the tumour
is mechanistically related to high IFP is supported by data from
Tong et al. [31]. Using similar xenograft tumour mouse models
they could show that application of a monoclonal antibody
directed against VEGF decreased the IFP of the tumours and
increased the penetration of tagged BSA used as repoter
molecule for tissue penetration. Furthermore, Klosowska-War-
dega et al. [33] could show that pharmacological inhibition of
PDGF- and VEGF-mediated signaling lead to a reduction of
tumour IFP and to an improved therapeutic effect of taxol that
needs to penetrate into the tumour in order to exert its effects.
In summary, our results show that antibody penetration into
tumours is restricted to areas around blood vessels. This
limitation of the penetration correlates with an increased IFP
within tumours and severely limits the access of the antibody to
the target. Therefore, lowering this IFP could greatly enhance
the success of diagnostics and therapeutic interventions based on
antibodies [34].
Figure 7. Vasculature of HT29 xenografted tumours visualized by DiI labelling. (A) Unequal distribution of the blood vasculature (red) of
a whole HT29 tumour vibratome slice (stitched of 610 objective lens images). (B) Magnification of the boxed area in A, showing immature blood
vessels (projection of a z series with z step size of 2.85 mm over 215 mm with610 objective lens). (C) Three-dimensional view of a section of B (z series
with z step size of 1.4 mm over 140 mm with640 objective lens) showing the irregular structure of blood vessels. All tissues were viewed by confocal
fluorescence microscopy (Nikon A1R confocal microscope with plan apo610/0.45 numerical aperture (NA) or plan fluo oil640/1.3 NA objective lens
and with the laser excitation wavelength of 561 nm and the emission of 595). Scale bars: 2000 mm for A, 200 mm for B.
doi:10.1371/journal.pone.0036258.g007
Figure 8. IFP measurements of HT29 xenograft tumours. (A) Typical pressure recording of a HT29 tumour. After adjusting the pressure at
0 mbar and insertion of the needle (arrow a) in the tumour the pressure increased and decreased rapidly and reaches a stable value of 16 mbar. To
test the fluid communication between pressure sensor and needle the tubing is compressed with a screw clamp (arrow b) which results in a sharp
increase of the pressure, then an exponential decrease, followed by another period of stabilization before decompressing the tubing (arrow c) which
produces a rapid decrease and an exponential increase. (B) Measurement of 6 different HT29 tumours showed a mean IFP of 11.9 (+/24) mbar.
doi:10.1371/journal.pone.0036258.g008
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